168 related articles for article (PubMed ID: 20516287)
1. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Pucci MJ; Ackerman M; Thanassi JA; Shoen CM; Cynamon MH
Antimicrob Agents Chemother; 2010 Aug; 54(8):3478-80. PubMed ID: 20516287
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
3. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
[TBL] [Abstract][Full Text] [Related]
4. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
Aubry A; Veziris N; Cambau E; Truffot-Pernot C; Jarlier V; Fisher LM
Antimicrob Agents Chemother; 2006 Jan; 50(1):104-12. PubMed ID: 16377674
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
7.
Tudó G; Lopez-Gavin A; Portell-Buj E; Freixes J; Vila J; Roman A; Monté MR; Gonzalez-Martin J
Microb Drug Resist; 2020 Sep; 26(9):1019-1022. PubMed ID: 32159449
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.
Maruri F; Sterling TR; Kaiga AW; Blackman A; van der Heijden YF; Mayer C; Cambau E; Aubry A
J Antimicrob Chemother; 2012 Apr; 67(4):819-31. PubMed ID: 22279180
[TBL] [Abstract][Full Text] [Related]
9. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
[TBL] [Abstract][Full Text] [Related]
10. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.
Kim H; Nakajima C; Yokoyama K; Rahim Z; Kim YU; Oguri H; Suzuki Y
Antimicrob Agents Chemother; 2011 Aug; 55(8):3661-7. PubMed ID: 21646485
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.
Pucci MJ; Podos SD; Thanassi JA; Leggio MJ; Bradbury BJ; Deshpande M
Antimicrob Agents Chemother; 2011 Jun; 55(6):2860-71. PubMed ID: 21464250
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
Matrat S; Veziris N; Mayer C; Jarlier V; Truffot-Pernot C; Camuset J; Bouvet E; Cambau E; Aubry A
Antimicrob Agents Chemother; 2006 Dec; 50(12):4170-3. PubMed ID: 17015625
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling.
Nandi S; Ahmed S; Saxena AK
SAR QSAR Environ Res; 2018 Feb; 29(2):151-170. PubMed ID: 29347843
[TBL] [Abstract][Full Text] [Related]
14. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
Coulibaly S; Cimino M; Ouattara M; Lecoutey C; Buchieri MV; Alonso-Rodriguez N; Briffotaux J; Mornico D; Gicquel B; Rochais C; Dallemagne P
Eur J Med Chem; 2020 Dec; 207():112821. PubMed ID: 32950907
[TBL] [Abstract][Full Text] [Related]
15. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.
Tan CK; Lai CC; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
J Antimicrob Chemother; 2009 Aug; 64(2):428-9. PubMed ID: 19454523
[No Abstract] [Full Text] [Related]
17. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
18. Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
Matrat S; Aubry A; Mayer C; Jarlier V; Cambau E
Antimicrob Agents Chemother; 2008 Aug; 52(8):2909-14. PubMed ID: 18426901
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanism of the acquisition of new-quinolone resistance in Mycobacterium leprae and M. tuberculosis and rapid differentiation methods for resistant bacilli].
Kim H; Suzuki H; Matsuoka M; Matsuba T; Yokoyama K; Nakajima C; Suzuki Y
Nihon Hansenbyo Gakkai Zasshi; 2011 Feb; 80(1):17-27. PubMed ID: 21404592
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
